MagForce AG (MF6) - Product Pipeline Analysis, 2018 Update

  • ID: 4400027
  • Company Profile
  • 34 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Curetis NV
  • Draegerwerk AG & Co. KGaA
  • MORE
MagForce AG (MagForce) is a medical device company that offers nanotechnology-based therapy for cancer treatment. The company’s products include NanoActivator, NanoTherm, NanoPlan and NanoTherm Therapy. Its NanoActivator creates a magnetic field that can be used to treat tumors in all areas of the body. MagForce’s NanoTherm is a liquid that reacts to the presence of magnetic field. The company’s NanoPlan uses the bioheat transfer equation to help the physician in charge estimate treatment temperatures and the magnetic field strength. Its products are used in the treatment of prostate cancer, pancreatic cancer, esophageal cancer and glioblastoma. The company operates through therapy centers located in Berlin, Munster, Kiel, Cologne and Frankfurt, Germany. MagForce is headquartered in Berlin, Germany.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company MagForce AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Curetis NV
  • Draegerwerk AG & Co. KGaA
  • MORE
  • MagForce AG Company Overview
  • MagForce AG Company Snapshot
  • MagForce AG Pipeline Products and Ongoing Clinical Trials Overview
  • MagForce AG - Pipeline Analysis Overview
  • MagForce AG - Key Facts
  • MagForce AG - Major Products and Services
  • MagForce AG Pipeline Products by Development Stage
  • MagForce AG Ongoing Clinical Trials by Trial Status
  • MagForce AG Pipeline Products Overview
  • NanoTherm - Brain Cancer
  • NanoTherm - Brain Cancer Product Overview
  • NanoTherm - Gastrointestinal Cancer
  • NanoTherm - Gastrointestinal Cancer Product Overview
  • NanoTherm - Pancreatic Carcinoma
  • NanoTherm - Pancreatic Carcinoma Product Overview
  • NanoTherm - Prostate Carcinoma
  • NanoTherm - Prostate Carcinoma Product Overview
  • NanoTherm - Prostate Carcinoma Clinical Trial
  • NanoTherm - Recurrent Glioblastoma
  • NanoTherm - Recurrent Glioblastoma Product Overview
  • Next-Generation Nanotherm
  • Next-Generation Nanotherm Product Overview
  • MagForce AG - Key Competitors
  • MagForce AG - Key Employees
  • MagForce AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • MagForce AG, Recent Developments
  • Jul 02, 2018: MagForce Announces Enrollment of First Patient in its Pivotal, Three-Stage, Single-Arm Study of Focal Ablation of Prostate Cancer with NanoTherm Therapy
  • Jun 14, 2018: MagForce Co-Sponsors the University Hospital of Munster’s Annual Brain Cancer Patient Event
  • Jun 12, 2018: MagForce Announces Collaboration Agreement for NanoTherm Therapy with Independent Public Clinical Hospital No. 4, Lublin, Poland
  • Jun 04, 2018: MagForce to host Lunch Symposium about Local Therapies for Malignant Gliomas at the 2018 meeting of the German Society of Neurosurgery (DGNC)
  • May 03, 2018: MagForce Publishes Financial Results for the Year 2017 and Operative Highlights
  • Feb 15, 2018: FDA expands treatment window for use of clot retrieval devices in certain stroke patients
  • Feb 10, 2018: MagForce USA Receives FDA Investigational Device Exemption Approval to Conduct A Clinical Trial With NanoTherm Therapy As Focal Ablation Treatment For Intermediate Risk Prostate Cancer
  • Nov 14, 2017: MagForce to participate at SNO 2017 Annual Meeting from November 16-19 in San Francisco, USA
  • Sep 29, 2017: MagForce Publishes Financial Results for the First Half of 2017 and Operative Highlights
  • Aug 10, 2017: MagForce announces positive results of 2017 Annual General Meeting
  • Appendix
  • Methodology
  • About
  • Contact
  • Disclaimer
List of Tables
  • MagForce AG Pipeline Products and Ongoing Clinical Trials Overview
  • MagForce AG Pipeline Products by Equipment Type
  • MagForce AG Pipeline Products by Indication
  • MagForce AG Ongoing Clinical Trials by Trial Status
  • MagForce AG, Key Facts
  • MagForce AG, Major Products and Services
  • MagForce AG Number of Pipeline Products by Development Stage
  • MagForce AG Pipeline Products Summary by Development Stage
  • MagForce AG Ongoing Clinical Trials by Trial Status
  • MagForce AG Ongoing Clinical Trials Summary
  • NanoTherm - Brain Cancer - Product Status
  • NanoTherm - Brain Cancer - Product Description
  • NanoTherm - Gastrointestinal Cancer - Product Status
  • NanoTherm - Gastrointestinal Cancer - Product Description
  • NanoTherm - Pancreatic Carcinoma - Product Status
  • NanoTherm - Pancreatic Carcinoma - Product Description
  • NanoTherm - Prostate Carcinoma - Product Status
  • NanoTherm - Prostate Carcinoma - Product Description
  • NanoTherm - Prostate Carcinoma - An Investigational Device Exemption, Phase III Study of NanoTherm therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer
  • NanoTherm - Recurrent Glioblastoma - Product Status
  • NanoTherm - Recurrent Glioblastoma - Product Description
  • Next-Generation Nanotherm - Product Status
  • Next-Generation Nanotherm - Product Description
  • MagForce AG, Key Employees
  • MagForce AG, Other Locations
  • MagForce AG, Subsidiaries
  • Glossary
List of Figures
  • MagForce AG Pipeline Products by Equipment Type
  • MagForce AG Pipeline Products by Development Stage
  • MagForce AG Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Draegerwerk AG & Co. KGaA
  • Curetis NV
  • Pulsion Medical Systems SE
  • German Cancer Research Center
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll